



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07C 255/57, C07D 295/12, A61K 31/275, A61P 11/00, 25/00, 1/00, 29/00	A1	(11) International Publication Number: WO 00/59873 (43) International Publication Date: 12 October 2000 (12.10.00)
(21) International Application Number: PCT/GB00/01252 (22) International Filing Date: 3 April 2000 (03.04.00) (30) Priority Data: 9907571.5 6 April 1999 (06.04.99) GB (71) Applicant (for all designated States except US): AS-TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE). (72) Inventor; and (75) Inventor/Applicant (for US only): BERNSTEIN, Peter, Robert [US/US]; 1800 Concord Pike, Wilmington, DE 19850-5437 (US). (74) Agent: PHILLIPS, Neil, Godfrey, Alasdair, AstraZeneca, Global Intellectual Property, P.O. Box 272, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TR (GB).	(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  *G00001*	
(54) Title: N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS		
(57) Abstract A compound having the general formula (I): $R^1R^2N-CH_2CH_2-CHAr^1-CH_2-NR^3-CO-R^4$ wherein: R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, aryl, C_{1-6} alkanoyl C_{1-6} alkoxy carbonyl or arylcarbonyl; any of such groups being optionally substituted; R^2 is hydrogen or C_{1-6} alkyl; or R^1 or R^2 are joined to form an optionally substituted morpholino ring; Ar^1 is phenyl mono- or di-substituted by halo; R^3 is hydrogen or C_{1-6} alkyl; R^4 is optionally substituted naphth-1-yl; or pharmaceutically acceptable salts thereof. These compounds antagonize the pharmacological actions of the endogenous neuropeptide tachykinins, particularly the neurokinin 1 (NK1) receptor.		

